At In Vivo, Roger Longman discusses the GlaxoSmithKline/Pfizer joint venture on HIV and how it addresses pharma's main concerns. "The GSK/Pfizer HIV joint venture is an interesting solution to both problems – the big/small paradox and the funding troubles. The new company is relatively small (first year projected sales: $2.4 billion); it's got its own managers; it makes its own R&D decisions," Longman writes. Jeremy Grushcow at the Cross-Border Biotech Blog adds, "I certainly hope it works, because it seems like it would be a bear to unwind.
May 28, 2009